Key result
Temporary active-fixation pacemakers allow ~38% of patients to avoid permanent pacemaker implantation.
Why the study?
Temporary active-fixation pacemakers may offer more secure lead placement, greater patient mobility, and reduced need for intensive care monitoring than conventional balloon-tipped temporary pacemakers, motivating evaluation of their safety and clinical utility across multiple pacing indications.
Does temporary active-fixation pacemaker (TAF-PM) placement allow safe discontinuation of temporary pacing without subsequent permanent pacemaker implantation in adults with temporary pacing indications?
Cohort (n=100)
No
Does temporary active-fixation pacemaker (TAF-PM) placement allow safe discontinuation of temporary pacing without subsequent permanent pacemaker implantation in adults with temporary pacing indications?
Temporary active-fixation pacing is a safe and reversible strategy that allows 38% of patients overall—and 75% of those with TAVR- or AMI-related conduction abnormalities—to avoid permanent pacemaker implantation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for temporary externalized pacemaker use; prospective trials needed before broader adoption.
BACKGROUND: Temporary active-fixation pacemakers (TAF-PMs), consisting of a screw-in pacing lead connected to an external generator, may offer advantages over conventional balloon-tipped temporary pacemakers, including more secure lead placement, greater patient mobility, and reduced need for intensive care monitoring. We evaluated the safety and clinical utility of this strategy across multiple pacing indications. METHODS: We conducted a single-center, retrospective study of 100 adults who underwent TAF-PM placement between June 2019 and November 2024. Through chart review, data were collected on demographics, pacing indications, duration of temporary pacing, complications, and subsequent need for permanent pacemaker implantation (PPMI). The primary outcome was successful discontinuation of temporary pacing without subsequent PPMI. RESULTS: Pacing indications included spontaneous progression of conduction system disease (60%), transcatheter aortic valve replacement (TAVR)-related conduction abnormalities (12%), acute myocardial infarction (AMI)-related conduction abnormalities (12%), and ongoing infection precluding PPMI (16%). Thirty-eight patients (38%) did not undergo subsequent PPMI. Among patients with TAVR- and AMI-related conduction abnormalities, 75% avoided PPMI. Three patients (3%) experienced lead dislodgement. No new infections, lead perforations, significant bleeding, or cardiac arrests attributable to the TAF-PM strategy were documented. CONCLUSION: Temporary pacing using a screw-in lead affixed to an external generator is safe, effective, and reversible across multiple clinical scenarios, allowing sufficient time to assess the need for permanent pacing.
No takes yet. Share an insight, caveat, or question.
Schiefer et al. (2026) conducted a cohort in Indications for temporary pacing (conduction system disease, TAVR- or AMI-related conduction abnormalities, ongoing infection precluding permanent pacemaker implantation) (n=100). Temporary active-fixation pacemaker (TAF-PM) placement was evaluated on Successful discontinuation of temporary pacing without subsequent permanent pacemaker implantation (PPMI). Temporary active-fixation pacemaker placement allowed 38% of patients overall to avoid permanent pacemaker implantation, with a 3% dislodgement rate.
Synapse has enriched 10 related papers. Consider them for comparative context: